⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ACRV News
Acrivon Therapeutics, Inc. Common Stock
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
globenewswire.com
ACRV
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ACRV
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
globenewswire.com
ACRV
Form 8-K
sec.gov
ACRV
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors
globenewswire.com
ACRV
Form 8-K
sec.gov
ACRV
Form 8-K
sec.gov
ACRV
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
globenewswire.com
ACRV
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress
globenewswire.com
ACRV
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory
globenewswire.com
ACRV